Home / Going-concern warnings / Vivos Therapeutics, Inc.

5/5Vivos Therapeutics, Inc. (VVOS): Going-concern doubt

Filed 2026-04-15 路 Form 10-K 路 Accession 0001493152-26-016854 nano

Market data

Price before filing: $1.35 (2026-04-14 close, split/dividend-adjusted)
Market cap at flag: $21.5M (2026-04-15) 路 Latest: $2.3M (2026-10-16)

What happened next

WindowVVOSSPYvs SPY
30 days-52.5%+6.4%-59.0%2026-05-15
90 days-69.7%+8.5%-78.2%2026-07-14
180 days-89.3%+12.6%-101.9%2026-10-12

Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.

Insider trading around this filing

90 days before the flag: 1 insider bought $1.8M (2 purchases)
30 days after: none reported.

DateInsiderTypeSharesPriceValue10b5-1 planSource
2026-03-31Skaff Michael C (+1 joint filer)
10% owner
Purchase1,044,777$1.34$1.4MnoForm 4
2026-03-31Skaff Michael C (+1 joint filer)
10% owner
Purchase308,848$1.34$414KnoForm 4
2026-04-15: red flag filed

Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2026-01-15 to 2026-05-15. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.

Verified excerpt

"As discussed in Note 2 to the consolidated financial statements, the Company has suffered recurring losses from operations that raise substantial doubt about its ability to continue as a going concern."

Quoted from the filing. Source

What this means

The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.

Going-concern opinion issued by: Baker Tilly US, LLP
Source: independent auditor report in Form 10-K (period 2025-12-31)

Why this score: in auditor's report

Read the original filing on SEC.gov →

Not investment advice. Automated summary; verify against the filing.

Get the weekly "Red Flags" newsletter

The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.

Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.

Form not showing? Subscribe on beehiiv →

Newsletter delivered by beehiiv. See our privacy policy.